Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CLBTBearishLegalnews

High materiality7/10

Cellebrite Faces Securities Investigation After Q2 Miss and CEO Change

Aug 24, 2026, 11:25 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Initial 29% stock drop and ongoing investigation create overhang; history shows such probes can trigger additional disclosures, settlements, or guidance revisions, magnifying downside before clarity.

AI summary

What happened, with direct paths to the underlying reporting

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations at Cellebrite (CLBT) following a Q2 miss and governance shift. Cellebrite reported ARR of $507.8 million and cut full-year ARR guidance by about $15 million, while appointing Shiv Ramji as CEO. The combination of regulatory risk and leadership upheaval could pressure CLBT's valuation in the near term.

Kaplan Fox investigating potential securities violations against Cellebrite (CLBT).
Q2 ARR $507.8M; ARR guidance cut midpoint by $15M.
CEO Tom Hogan replaced by Shiv Ramji; immediate effect.
Cellebrite stock down 29% to $10.80 on Aug 13.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Cellebrite Faces Securities Investigation After Q2 Miss and CEO Change

Cellebrite DI Ltd. (CLBT) Q1 Earnings and Revenues Surpass Estimates